Company intelligence / Profile preview
Neuropeutics
Mississauga, Ontario, Canadaneuropeutics.ca ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
Neuropeutics has demonstrated that its lead compound, JRMS-22, reduces the aggregation of neurotoxic proteins (notably TDP-43) by approximately 30% in mouse models of ALS and frontotemporal dementia, and similarly affects other proteinopathies in preclinical studies. The therapy is being optimized for oral administration and advanced toward IND-enabling studies and clinical trials[5][7].
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
AbbVieSpinUp (University of Toronto Mississauga)LifeArc
Beyond the preview
Go deeper on Neuropeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuropeutics.